Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Bach Biosciences","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma and Bach Biosciences Announce Licensing and Partnership for canSEEK\u2122 Pan-Cancer Targeting Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Oncology Clinical Drug Pipeline Developments & Deals by Bach Biosciences

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Bach Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              POINT Biopharma and Bach Biosciences Announce Licensing and Partnership for canSEEK™ Pan-Cancer Targeting Technology

              Details:

              The agreement provides POINT the exclusive global rights to commercialize the groundbreaking can-SEEK™ tumor targeting technology. With canSEEK™, POINT expands its theragnostic oncology pipeline to include PNT2004, a pan tumor treatment.

              Lead Product(s): PNT2004

              Therapeutic Area: Oncology Product Name: PNT2004

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Point Biopharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY